RT-Banner-2020C.gif

China Daily

News> Nation> Content
Sunday, October 18, 2020, 10:14
Lancet: Preliminary results show Chinese vaccine candidate safe
By Xinhua
Sunday, October 18, 2020, 10:14 By Xinhua

A sample of the COVID-19 inactivated vaccine is seen at a vaccine production plant of China National Pharmaceutical Group (Sinopharm) in Beijing, capital of China, April 10, 2020. (PHOTO / Xinhua)

LONDON - A Chinese COVID-19 vaccine candidate based on the inactivated whole SARS-CoV-2 virus is safe and elicits an antibody response, according to the findings from a small early-phase randomised clinical trial published Thursday in The Lancet Infectious Diseases journal.

Participants aged 60 and older were slower to respond, taking 42 days before antibodies were detected in all recipients compared with 28 days for participants aged 18-59

The latest study included participants aged between 18 and 80 years, and found that antibody responses were induced in all recipients. Participants aged 60 and older were slower to respond, taking 42 days before antibodies were detected in all recipients compared with 28 days for participants aged 18-59.

The trial was not designed to assess efficacy of the vaccine, so it is not possible to say whether the antibody responses induced by the vaccine, called BBIBP-CorV, are sufficient to protect people from SARS-CoV-2 infection.

READ MORE: Lancet: China's COVID-19 vaccine shows promising results

The authors also noted that interpretation of the results of this study is limited by the short duration of follow-up.

According to The Lancet, there are currently 42 vaccines for COVID-19 in clinical trials. Vaccine candidates in clinical trials vary in type and include DNA plasmid vaccines, inactivated virus vaccines, adenovirus-vectored vaccines, RNA vaccines, protein subunit vaccines and virus-like particle vaccines. Some of these have already proved safe and able to elicit immune responses in early phase clinical trials.

ALSO READ: Lancet retracts hydroxychloroquine risks article

"Our findings indicate that a booster shot is necessary to achieve the greatest antibody responses against SARS-CoV-2 and could be important for protection. This provides useful information for a phase 3 trial," said Yang Xiaoming, one of the authors of the study and a professor from the Beijing Institute of Biological Products.

Share this story

CHINA DAILY
HONG KONG NEWS
OPEN
Please click in the upper right corner to open it in your browser !